In community-acquired pneumonia, adding oral clarithromycin to standard care increased early clinical response.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 38710079.
- Also identified by DOI 10.7326/J24-0022.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A, et al. <b>Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial.</b> Lancet Respir Med. 2024;12:294-304. 38184008.
Medical subject headings
- Anti-Bacterial Agents
- Clarithromycin
- Community-Acquired Infections